Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
Nov 13, 2026, 9:43 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
New caregiver-reported pediatric data may support future label expansion or inform prescribing and commercial uptake, which could increase revenue if regulators or prescribers act on the findings; impact depends on statistical robustness, safety, and regulatory decisions.
AI summary
What happened, with direct paths to the underlying reporting
Arcutis presented new caregiver-reported outcomes data for ZORYVE 0.05% in infants (≥3 months) at the ACAAI meeting.
Arcutis presented new caregiver-reported outcomes data supporting ZORYVE (roflumilast) Cream 0.05% for mild-to-moderate atopic dermatitis in infants down to 3 months at the ACAAI Annual Scientific Meeting.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
